BACKGROUND: Near-tetraploid (model #81-103) and near-triploid (model #67-81) karyotypes are found in around 1% of childhood acute lymphoblastic leukemia. Due to its rarity, these two cytogenetic subgroups are generally included in the hyperdiploid group (model # > 51). Therefore separate informations about these two subgroups are limited to a few reports. Some studies found that near-tetraploidy is relatively more frequent in higher median ages and it is associated to Frech-American-British Classification subtype L2. Although the mechanisms by which leukemic blast cells divide is still unclear, studies have suggested that hyperdiploidy, near-triploidy and near-tetraploidy do not seem to share the same mechanism. FINDINGS: Herewith, we present a new childhood T-acute lymphoblastic leukemia case of near-tetraploid karyotype with loss of two p53-gene copies, characterized in detail by cytogenetic and molecular studies. CONCLUSION: We suggest that p53 is a good target gene to be screened, once p53 is one of the main effectors of cell cycle checkpoints.
BACKGROUND: Near-tetraploid (model #81-103) and near-triploid (model #67-81) karyotypes are found in around 1% of childhood acute lymphoblastic leukemia. Due to its rarity, these two cytogenetic subgroups are generally included in the hyperdiploid group (model # > 51). Therefore separate informations about these two subgroups are limited to a few reports. Some studies found that near-tetraploidy is relatively more frequent in higher median ages and it is associated to Frech-American-British Classification subtype L2. Although the mechanisms by which leukemic blast cells divide is still unclear, studies have suggested that hyperdiploidy, near-triploidy and near-tetraploidy do not seem to share the same mechanism. FINDINGS: Herewith, we present a new childhood T-acute lymphoblastic leukemia case of near-tetraploid karyotype with loss of two p53-gene copies, characterized in detail by cytogenetic and molecular studies. CONCLUSION: We suggest that p53 is a good target gene to be screened, once p53 is one of the main effectors of cell cycle checkpoints.
Authors: Hasmik Mkrtchyan; Daniela Ribeiro Garcia Ney; Eliane Soares de Ventura; Thomas Liehr; Gabriel Rafael Felix; Terezinha de Jesus Marques-Salles; Eliana Abdelhay; Maria Luiza Macedo Silva Journal: Cancer Genet Cytogenet Date: 2010-02
Authors: Susana C Raimondi; Yinmei Zhou; Sheila A Shurtleff; Jeffrey E Rubnitz; Ching-Hon Pui; Frederick G Behm Journal: Cancer Genet Cytogenet Date: 2006-08
Authors: Petr Lemez; Andishe Attarbaschi; Marie C Béné; Yves Bertrand; Gianluigi Castoldi; Erik Forestier; Richard Garand; Oskar A Haas; Sandrine Kagialis-Girard; Wolf-Dieter Ludwig; Estella Matutes; Ester Mejstríková; Marie-Pierre Pages; Winfried Pickl; Anna Porwit; Alberto Orfao; Richard Schabath; Jan Starý; Herbert Strobl; Pascaline Talmant; Mars B van't Veer; Zuzana Zemanová Journal: Eur J Haematol Date: 2010-10 Impact factor: 2.997
Authors: Andishe Attarbaschi; Georg Mann; Margit König; Manuel Steiner; Michael N Dworzak; Helmut Gadner; Oskar A Haas Journal: Genes Chromosomes Cancer Date: 2006-06 Impact factor: 5.006
Authors: C H Pui; A J Carroll; D Head; S C Raimondi; J J Shuster; W M Crist; M P Link; M J Borowitz; F G Behm; V J Land Journal: Blood Date: 1990-08-01 Impact factor: 22.113
Authors: Cristina Marletta; Roberto Valli; Barbara Pressato; Lydia Mare; Giuseppe Montalbano; Giuseppe Menna; Giuseppe Loffredo; Maria Ester Bernardo; Luciana Vinti; Simona Ferrari; Alessandra Di Cesare-Merlone; Marco Zecca; Francesco Lo Curto; Franco Locatelli; Francesco Pasquali; Emanuela Maserati Journal: Mol Cytogenet Date: 2012-10-01 Impact factor: 2.009